Phase 1

Clinical Trial NameClinical Trial Full TitlePrincipal InvestigatorProject site statusClinical trials gov number
(Alkermes) ALKS 4230-001 / ARTISTRY-2A Phase 1/2 Study of ALKS 4230 Administered Subcutaneously as Monotherapy and in Combination with Pembrolizumab in Subjects with Advanced Solid Tumors- ARTISTRY-2 (001)Hirte, Dr HalOpen to recruitmentNCT03861793
(Merck) MK-4830-001A Phase 1 Open Label, Multi-Arm, Multicenter Study of MK-4830 as Monotherapy and in Combination with Pembrolizumab for Participants with Advanced Solid TumorsHotte, Dr SebastienOpen to recruitmentNCT03564691
(SignalChem) SLC-391-101A Phase 1, Open-label, Dose-escalation, and Dose-expansion Study of the Safety and Pharmacokinetics of the AXL Inhibitor SLC-391 Administered Orally to Subjects with Solid TumoursHotte, Dr SebastienOpen to recruitmentNCT03990454
(Alkermes) ALK4230-A101 / ARTISTRYA Phase 1 Study of ALKS 4230 Administered Intravenously as Monotherapy and in Combination with Pembrolizumab in Subjects with Advanced Solid TumorsHirte, Dr HalRecruitment on hold - COVID-19NCT02799095
(Astellas) 1951-CL-0101A Phase 1b Study of ASP1951, a GITR Agonistic Antibody, as a Single Agent and in Combination with Pembrolizumab in Subjects with Advanced Solid TumorsJuergens, Dr RosalynSuspended/On holdNCT03799003
(Fusion) FPX-01-01A Phase 1 Study of [225Ac]-FPI-1434 Injection in Patients with Advanced Solid TumoursJuergens, Dr RosalynSuspended/On holdNCT03746431
(Mundipharma Research) EDO-S101-1002A Phase 1/2 Study to Investigate the safety, Pharmacokinetics and Efficacy of Tinostamustine, a First-in-Class Alkylating Histone Deacetylase Inhibition (HDACi) Fusion Molecule, in Patients with Advanced Solid TumorsEllis, Dr PeterSuspended/On holdNCT03345485
Download PDF